On June 30, 2017 AskAt Inc. reported that AskAt received a notice of allowance dated June 30, 2017 from Office of the Controller General of Patent, Designs & Trade Marks in connection with the Application No. 817/DELNP/2006, a substance patent for its EP4 antagonist(AAT-007) (Press release, AskAt, JUN 30, 2017, View Source [SID1234535062]).
On June 30, 2017 Pfizer Inc. (NYSE:PFE) reported that the European Commission has approved BESPONSA (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) (Press release, Pfizer, JUN 30, 2017, View Source [SID1234519739]). This indication includes treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor ALL. Adults with Ph+ relapsed or refractory CD22-positive B-cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI). With this approval, BESPONSA becomes the first and only antibody drug conjugate (ADC) available for patients with this type of leukemia in the European Union (EU).
"The European Commission’s approval of BESPONSA represents an important milestone for patients, the oncology community and Pfizer," said Andreas Penk, M.D., regional president, Pfizer Oncology. "This is the first approval for BESPONSA and provides patients in the EU, who are battling an especially hard-to-treat leukemia, with a new treatment option beyond chemotherapy."
ALL is an aggressive type of leukemia that can be fatal within a matter of months if left untreated.1 The goal of treatment in relapsed or refractory (resistant) ALL is to achieve complete remission without excessive toxicity so patients may proceed to additional therapeutic intervention, particularly stem cell transplant, which is the most recognized option to prolong patient survival, maintenance therapy or other therapy.2 In adult patients with relapsed or refractory ALL, median overall survival is just three to six months.3,4,5 The current standard of care is intensive chemotherapy6, which is effective in less than 50 percent of relapsed or refractory patients and associated with poor long-term survival, high toxicities, lengthy inpatient stays and continuous infusions.7
"Acute lymphoblastic leukemia that has recurred or is refractory following first-line therapy is a rare and rapidly progressive disease with poor prognosis," said Professor David Marks, Department of Hematology, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. "The approval of BESPONSA (inotuzumab ozogamicin) provides a much needed treatment option for physicians and patients alike, that may help improve outcomes for some of the most vulnerable leukemia patients in Europe."
The European Commission’s approval of BESPONSA is supported by results from the Phase 3 INO-VATE ALL trial, in which 326 adult patients with relapsed or refractory B-cell precursor ALL were enrolled and which compared BESPONSA to standard of care chemotherapy. The INO-VATE ALL study had two primary endpoints, complete response with or without hematologic recovery (CR/CRi) and overall survival (OS). Results from the trial were published in The New England Journal of Medicine in June 2016.
In the U.S., BESPONSA received Breakthrough Therapy designation from the Food and Drug Administration (FDA) in October 2015 for ALL. A Biologics License Application (BLA) for BESPONSA for the treatment of adult patients with relapsed or refractory B-cell precursor ALL was accepted for filing and granted Priority Review by the FDA in February 2017. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is August 2017.
With a growing hematology pipeline, Pfizer is committed to extending therapeutic progress in acute and chronic leukemias that leverage select pathways and mechanism of actions (MOAs). Specifically, our investigational products aim to treat some of the hardest to treat leukemias and lymphomas including, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and mantle cell lymphoma (MCL).
Indication for BESPONSA (Inotuzumab Ozogamicin) in the EU
BESPONSA is approved as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor ALL in the EU. Adult patients with Ph+ relapsed or refractory B-cell precursor ALL should have failed treatment with at least one TKI.
Important Safety Information for BESPONSA (Inotuzumab Ozogamicin) in the EU
The most common (≥ 20%) adverse reactions associated with BESPONSA were thrombocytopenia (51%), neutropenia (49%), infection (48%), anaemia (36%), leukopenia (35%), fatigue (35%), haemorrhage (33%), pyrexia (32%), nausea (31%), headache (28%), febrile neutropenia (26%), increased transaminases (26%), abdominal pain (23%), increased gamma-glutamyltransferase (21%), and hyperbilirubinaemia (21%).
The most common (≥ 2%) serious adverse reactions associated with BESPONSA were infection (23%), febrile neutropenia (11%), haemorrhage (5%), abdominal pain (3%), pyrexia (3%), veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) (2%), and fatigue (2%).
In the Phase 3 INO-VATE ALL trial (N=164 patients treated with BESPONSA), VOD/SOS was reported in 22 (13%) patients including 5 (3%) patients during study therapy or in follow-up without an intervening hematopoietic stem cell transplant (HSCT). Among the 77 patients who proceeded to a subsequent HSCT (6 of whom received additional salvage therapy after treatment with BESPONSA before proceeding to HSCT), VOD/SOS was reported in 17 (22%) patients. Five of the 17 VOD/SOS events that occurred post-HSCT were fatal.
VOD/SOS was reported up to 56 days after the last dose of BESPONSA without an intervening HSCT. The median time from HSCT to onset of VOD/SOS was 15 days (range: 3-57 days). Of the 5 patients who experienced VOD/SOS during treatment with BESPONSA but without an intervening HSCT, 2 patients had also received an HSCT before BESPONSA treatment.
Among patients who proceeded to HSCT after BESPONSA treatment, VOD/SOS was reported in 5/11 (46%) patients who received an HSCT both prior to and after BESPONSA treatment and 12/66 (18%) patients who only received an HSCT after BESPONSA treatment.
The EU Summary of Product Characteristics (SmPC) is available at View Source
About BESPONSA (Inotuzumab Ozogamicin)
BESPONSA is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody (mAb) targeting CD22, a cell surface antigen expressed on cancer cells in almost all B-ALL patients, linked to a cytotoxic agent.8 When BESPONSA binds to the CD22 antigen on B-cells, it is internalized into the cell, where the cytotoxic agent calicheamicin is released to destroy the cell.9
BESPONSA originates from a collaboration between Pfizer and Celltech, now UCB. Under the terms of this agreement, Pfizer has sole responsibility for all manufacturing and clinical development activities for this molecule. Pfizer also collaborated with SFJ Pharmaceuticals Group (SFJ) on the registrational program (INO-VATE ALL) for BESPONSA.
On June 30, 2017 Kyowa Hakko Kirin Co., Ltd. (Headquarters:Tokyo; President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announces that it has initiated a Phase 3 clinical study in Japan of mogamulizumab (code No. : KW-0761)*1 in patients with HTLV-1-associated myelopathy (Press release, Kyowa Hakko Kirin, JUN 30, 2017, View Source [SID1234519735]).
HTLV-1-associated myelopathy (HAM) manifests as inflammation in the spinal cord caused by T-lymphocytes infected with human T-cell leukemia virus type 1 (HTLV-1). The disease progresses slowly and is accompanied by symptoms such as walking difficulties, numbness, difficulty passing urine, and constipation. A 2010 epidemiological survey estimated that approximately 3,000 patients in Japan have developed HAM, where it is a designated intractable disease*2. Mogamulizumab is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4).
Mogamulizumab utilizes its enhanced ADCC activity to eliminate CCR4-positive T-lymphocytes infected with HTLV-1, and therefore is expected to alleviate symptoms in patients with HAM. Kyowa Hakko Kirin started the Phase 3 study based on the results of the investigatorinitiated clinical trials (Phase 1/2a study (completed) and the long-term study (ongoing)) led by Dr. Yoshihisa Yamano, Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine. The purpose of the Phase 3 study is to evaluate the efficacy and safety of mogamulizumab in patients with HAM.
"HAM is a severe disease which causes long term myelopathic symptoms, such as lower limb paralysis, pain, dysuria, and constipation, and for which there are no currently effective treatments." said Mitsuo Satoh, Ph.D., Head of Research and Development Division of Kyowa Hakko Kirin. "We hope mogamulizumab will be a treatment option for patients with HAM."
The Kyowa Hakko Kirin Group companies strive to contribute to the health and wellbeing of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
Target Disease HTLV-1-associated myelopathy (HAM)
Design Randomized, double-blind, placebo-controlled study with an open label study
Target number of subjects 52
Primary endpoint Improvement in the Osame’s Motor Disability Score (OMDS)
Publicized information ClinicalTrial.gov: NCT03191526 *1
About mogamulizumab (KW-0761)
Mogamulizumab is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). CCR4 is frequently expressed in certain hematologic cancer cells, but also expressed in T-lymphocytes infected with HTLV-1. Mogamulizumab is manufactured using Kyowa Hakko Kirin’s POTELLIGENT technology that is related to increased ADCC activity. It was approved for sale for the first time globally in Japan, and since March 2012 has been sold as an approved drug (brand name: POTELIGEO) for relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma (ATL). Furthermore, mogamulizumab obtained approval for additional indications in Japan for relapsed or refractory CCR4-positive peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) in March 2014 as well as for chemotherapy-naïve CCR4-positive ATL in December 2014. *2
About designated intractable diseases
Designated intractable diseases are diseases covered by medical subsidies as set forth in Article 5 of the Law for Medical Treatment of Patients with Intractable Diseases enacted in May 2014 in Japan. The designation is made by the Minister of Health, Labor, and Welfare when quality and appropriate medical treatment are judged to be imperative for patients with such a disease based on the opinion of the Health Science Council.
On June 29, 2017 Cytovation AS, a privately held biotech company developing CyPep-1 for the treatment of skin disorders, reported that it has raised NOK 20m in a private funding round. The financing was led by a group of private investors in Norway and the Company will use these funds to advance lead product CyPep-1 into a Phase I clinical trial (Press release, Cytovation, JUN 29, 2017, View Source [SID1234561558]).
Cytovation is developing CyPep-1, a peptide consisting of 27 amino acids that selectively targets cutaneous warts through the destruction of the cell membrane and creating an immune response through the release of antigens. These funds will enable Cytovation to conduct pre-clinical toxicology studies and GMP manufacturing of CyPep-1 as a topical cream for the treatment of warts caused by the human papilloma virus (HPV). This is a completely novel treatment strategy to treat a common disease which has already undergone extensive testing and quality control and also has applications in other dermatological diseases.
Cytovation’s CEO, Kjell Inge Arnevig, commented on the financing: "We have been encouraged by the continuing support of our new and existing investors. These funds will allow us to move through toxicology studies and formulation towards our planned Phase I clinical trial for CyPep-1 with initial results expected during 2018."